| Biomarker ID | 1321 |
| PMID | 24477576 |
| Year | 2014 |
| Biomarker | miR-25; miR-101;miR-628-5p |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Serum |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miR-25):- DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity; nuclear chromatin; chromatin; nuclear chromosome Pathways Include(miR-101):- DNA binding; Gene expression (Transcription); Generic Transcription Pathway; RNA Polymerase II Transcription; DNA-binding transcription factor activity, RNA polymerase II-specific Pathways Include(miR-628-5p):- cation binding; metal ion binding; DNA-binding transcription factor activity; DNA binding; DNA-binding transcription factor activity, RNA polymerase II-specific |
| Experiment | African Americans Vs Caucasian Americans with PCa |
| Type of Biomarker | Diagnostic |
| Cohort | 6 African Americans and 6 Caucasian Americans with Prostate Cancer (PCa) were selected for analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | miR-25, miR-101, miR-628-5p |